$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-K Financial Statement

#000114420414039508 Filed on June 25, 2014

Income Statement

Concept	2014 Q2	2013 Q1	2013
Revenue	$937.0K	$368.0K	$1.101M
YoY Change	92.01%	104.44%	0.05%
Cost Of Revenue	$597.2K	$520.0K	$1.588M
YoY Change	37.83%	57.58%	-0.14%
Gross Profit	$339.0K	-$153.0K	-$487.3K
YoY Change	516.36%	2.0%	-0.55%
Gross Profit Margin	36.18%	-41.58%	-44.28%
Selling, General & Admin	$1.428M	$1.410M	$5.412M
YoY Change	16.84%	20.51%	0.03%
% of Gross Profit	421.19%
Research & Development	$79.24K	$120.0K	$425.4K
YoY Change	-14.46%	-20.0%	-1.06%
% of Gross Profit	23.38%
Depreciation & Amortization	$55.14K	$80.00K	$394.0K
YoY Change	-38.35%	-11.11%	1.02%
% of Gross Profit	16.27%
Operating Expenses	$1.507M	$1.530M	$5.837M
YoY Change	14.63%	15.91%	-0.05%
Operating Profit	-$1.168M	-$1.681M	-$6.324M
YoY Change	-7.3%	14.35%	-0.09%
Interest Expense	$1.129M	-$40.00K	$72.86K
YoY Change	1273.01%	-80.0%	-221.44%
% of Operating Profit
Other Income/Expense, Net	$953.00
YoY Change
Pretax Income	-$2.296M	-$1.720M	-$6.381M
YoY Change	73.45%	2.99%	0.01%
Income Tax	$1.600K	$0.00	$1.600K
% Of Pretax Income
Net Earnings	-$2.297M	-$1.717M	-$6.382M
YoY Change	73.49%	2.81%	0.04%
Net Earnings / Revenue	-245.14%	-466.58%	-579.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$460.0K	-$546.0K	-$4.808M
COMMON SHARES
Basic Shares Outstanding	59.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2013 Q1	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.0K	$600.0K	$400.0K
YoY Change	0.0%	-86.96%	-33.33%
Cash & Equivalents	$170.5K	$563.1K	$400.0K
Short-Term Investments
Other Short-Term Assets	$81.42K	$138.9K	$200.0K
YoY Change	-55.99%	-53.7%	100.0%
Inventory	$38.60K	$39.21K	$0.00
Prepaid Expenses
Receivables	$492.9K	$217.1K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$783.4K	$958.3K	$1.100M
YoY Change	-4.82%	-81.21%	10.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$364.7K	$505.5K	$400.0K
YoY Change	-36.57%	-27.79%	-20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$541.5K	$797.5K	$600.0K
YoY Change	-35.48%	-27.5%	-25.0%
TOTAL ASSETS
Total Short-Term Assets	$783.4K	$958.3K	$1.100M
Total Long-Term Assets	$541.5K	$797.5K	$600.0K
Total Assets	$1.325M	$1.756M	$1.700M
YoY Change	-20.3%	-71.68%	-5.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$500.0K	$900.0K	$600.0K
YoY Change	-37.5%	125.0%	-33.33%
Accrued Expenses	$500.0K	$200.0K	$500.0K
YoY Change	66.67%	0.0%	150.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.300M	$1.400M	$3.000M
YoY Change	-43.48%	250.0%	114.29%
Total Short-Term Liabilities	$2.400M	$2.497M	$4.000M
YoY Change	-28.95%	127.04%	60.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.300M	$0.00
YoY Change	-100.0%	-7.14%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$1.300M	$0.00
YoY Change	-100.0%	-7.14%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.400M	$2.497M	$4.000M
Total Long-Term Liabilities	$0.00	$1.300M	$0.00
Total Liabilities	$2.400M	$3.819M	$4.000M
YoY Change	-48.77%	52.76%	5.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.92M	-$66.31M
YoY Change	31.46%
Common Stock	$87.86M	$64.25M
YoY Change	35.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.058M	-$2.063M	-$2.300M
YoY Change
Total Liabilities & Shareholders Equity	$1.325M	$1.756M	$1.700M
YoY Change	-20.3%	-71.68%	-5.56%

Cashflow Statement

Concept	2014 Q2	2013 Q1	2013
OPERATING ACTIVITIES
Net Income	-$2.297M	-$1.717M	-$6.382M
YoY Change	73.49%	2.81%	0.04%
Depreciation, Depletion And Amortization	$55.14K	$80.00K	$394.0K
YoY Change	-38.35%	-11.11%	1.02%
Cash From Operating Activities	$917.0K	-$1.110M	-$4.380M
YoY Change	-178.31%	-47.39%	-8.56%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$110.0K	$156.2K
YoY Change	-100.0%	450.0%	-186.78%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$110.0K	-$140.0K
YoY Change	-100.0%	450.0%	-22.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	720.0K	1.190M	4.330M
YoY Change	-25.52%	-69.87%	375.82%
NET CHANGE
Cash From Operating Activities	$917.0K	-1.110M	-4.380M
Cash From Investing Activities	0.000	-110.0K	-140.0K
Cash From Financing Activities	720.0K	1.190M	4.330M
Net Change In Cash	$917.0K	-30.00K	-190.0K
YoY Change	-373.26%	-101.65%	-95.32%
FREE CASH FLOW
Cash From Operating Activities	$917.0K	-$1.110M	-$4.380M
Capital Expenditures	$0.00	-$110.0K	$156.2K
Free Cash Flow	$917.0K	-$1.000M	-$4.536M
YoY Change	-170.42%	-52.15%	-1.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	214553	USD
CY2013Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	38000	USD
CY2014Q1	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	802600	USD
CY2013Q1	cyrx	Accrued Paid Time Off Current AccruedPaidTimeOffCurrent	92376	USD
CY2014	cyrx	Adjustments To Additional Paid In Capital Induced Conversion Costs AdjustmentsToAdditionalPaidInCapitalInducedConversionCosts	13713767	USD
CY2013	cyrx	Adjustments To Additional Paid In Capital Offering Costs In Connection With Private Placement Offering AdjustmentsToAdditionalPaidInCapitalOfferingCostsInConnectionWithPrivatePlacementOffering	-103542	USD
CY2013Q1	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	466200	USD
CY2014Q1	cyrx	Accrued Paid Time Off Current AccruedPaidTimeOffCurrent	155166	USD
CY2006Q2	cyrx	Aggregate Monthly Principal Payment AggregateMonthlyPrincipalPayment	2500	USD
CY2014Q1	cyrx	Aggregate Principal Payment AggregatePrincipalPayment	8000	USD
CY2014Q1	cyrx	Cash Exceeds Fdic Insurance Limits CashExceedsFdicInsuranceLimits	159000	USD
CY2013Q1	cyrx	Cash Exceeds Fdic Insurance Limits CashExceedsFdicInsuranceLimits	214000	USD
CY2014	cyrx	Consulting Service Fee ConsultingServiceFee	395300	USD
CY2013	cyrx	Consulting Service Fee ConsultingServiceFee	401100	USD
CY2014Q1	cyrx	Contingent Shares Receivable ContingentSharesReceivable	150000	shares
CY2014Q1	cyrx	Cryogenic Shippers CryogenicShippers	1037286	USD
CY2013Q1	cyrx	Cryogenic Shippers CryogenicShippers	962565	USD
CY2014	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued	478229	USD
CY2013	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued		USD
CY2014	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	30120	USD
CY2013	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	38475	USD
CY2014Q1	cyrx	Deposits And Other Assets DepositsAndOtherAssets	9358	USD
CY2013Q1	cyrx	Deposits And Other Assets DepositsAndOtherAssets	19744	USD
CY2014	cyrx	Income Tax Reconciliation Induced Conversion Costs IncomeTaxReconciliationInducedConversionCosts	4663000	USD
CY2013	cyrx	Income Tax Reconciliation Induced Conversion Costs IncomeTaxReconciliationInducedConversionCosts		USD
CY2014	cyrx	Income Tax Reconciliation Warrant Adjustment IncomeTaxReconciliationWarrantAdjustment	-7000	USD
CY2013	cyrx	Income Tax Reconciliation Warrant Adjustment IncomeTaxReconciliationWarrantAdjustment	-6000	USD
CY2014	cyrx	Increased In Monthly Principal Payment IncreasedInMonthlyPrincipalPayment	2500	USD
CY2014	cyrx	Maturity Period Of Remaining Unpaid Principal And Accrued Interest MaturityPeriodOfRemainingUnpaidPrincipalAndAccruedInterest	2015-03-01
CY2014Q1	cyrx	Maximum Amount Of Aggregate Monthly Principal Payment MaximumAmountOfAggregateMonthlyPrincipalPayment	10000	USD
CY2014	cyrx	Minimum Amount Of Additional Compensation MinimumAmountOfAdditionalCompensation	2000000	USD
CY2014	cyrx	Offering Costs In Connection With Equity Financing Included In Accounts Payable OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable		USD
CY2013	cyrx	Offering Costs In Connection With Equity Financing Included In Accounts Payable OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable	53747	USD
CY2013	cyrx	Offering Costs Related To Private Placement OfferingCostsRelatedToPrivatePlacement	103542	USD
CY2014	cyrx	Release Of Restricted Cash For Repayment Of Convertible Debentures Payable ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable		USD
CY2013	cyrx	Release Of Restricted Cash For Repayment Of Convertible Debentures Payable ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable	251368	USD
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	579678	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	858709	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	515825	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	217097	USD
CY2014Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	80328	USD
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59987846	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	dei	Entity Public Float EntityPublicFloat	27964500	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	Cryoport, Inc.
CY2013Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	85554	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1076784	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	899265	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83512399	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64210412	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	678119	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	693180	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	478229	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24600	USD
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	8700	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	678915	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17514	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92200	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	112300	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6680041	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	411762	shares
CY2014Q1	us-gaap	Assets Assets	1709950	USD
CY2013Q1	us-gaap	Assets Assets	1755797	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	1111614	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	958305	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369581	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563104	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4617535	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-193523	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4054431	USD
CY2014Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	262856	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	312856	shares
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	73088548	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59979954	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37760628	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59979954	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37760628	shares
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	59980	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	37761	USD
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong><em>Concentrations of Credit Risk</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") with basic deposit insurance coverage limits up to $250,000 per owner. At March 31, 2014 and 2013, the Company had cash balances of approximately $159,000 and $214,000, respectively, which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <strong><em> </em></strong></p> <!--EndFragment--></div> </div>
CY2014Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1622359	USD
CY2013Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1304419	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	2222988	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	1587823	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4127201	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	184750	USD
CY2013Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2013Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2014Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15379000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13505000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	60000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	51000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1651000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1319000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	135000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	32000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17225000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14907000	USD
CY2014	us-gaap	Depreciation Depreciation	219400	USD
CY2013	us-gaap	Depreciation Depreciation	281700	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	311590	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	393959	USD
CY2014Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities		USD
CY2013Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	20848	USD
CY2014	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-16066	USD
CY2013	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-51033	USD
CY2014	us-gaap	Dividends Preferred Stock DividendsPreferredStock		USD
CY2013	us-gaap	Dividends Preferred Stock DividendsPreferredStock		USD
CY2014Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	555500	USD
CY2013Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	651500	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	454288	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217432	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	521255	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	429078	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	62884	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	19616	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	19617	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	28199	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	49770	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	-163000	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	-111000	USD
CY2012Q4	us-gaap	Gross Profit GrossProfit	-62000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	-153000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	701341	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	701341	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	180086	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	272263	USD
CY2014Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	30746	USD
CY2013Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	30746	USD
CY2014	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		USD
CY2013	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17046	USD
CY2014	us-gaap	Gross Profit GrossProfit	436955	USD
CY2013	us-gaap	Gross Profit GrossProfit	-487284	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	55000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	72000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	167000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	143000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19563826	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6380833	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2318000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2319000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6650000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2169000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4600	USD
CY2013	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	215600	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-327000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-359000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome		USD
CY2013	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-1000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-221929	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	443568	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	323604	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	70973	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	236856	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-18564	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	108038	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	39558	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9509	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12542	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26588	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-34912	USD
CY2014	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	13713767	USD
CY2013	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	29703	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	39212	USD
CY2014	us-gaap	Interest Expense InterestExpense	784454	USD
CY2013	us-gaap	Interest Expense InterestExpense	72861	USD
CY2014	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	36500	USD
CY2013	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	42200	USD
CY2014	us-gaap	Interest Paid InterestPaid		USD
CY2013	us-gaap	Interest Paid InterestPaid	15676	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11420	USD
CY2013Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10679	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	18283	USD
CY2013Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	28533	USD
CY2014Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	30913	USD
CY2013Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	30913	USD
CY2014Q1	us-gaap	Liabilities Liabilities	4014445	USD
CY2013Q1	us-gaap	Liabilities Liabilities	3819072	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1709950	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1755797	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4014445	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2497408	USD
CY2014Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	386731	USD
CY2013Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	380526	USD
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 1. Nature of the Business</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Cryoport Inc. (the "Company", "Cryoport" or "we") is a Nevada corporation originally incorporated under the name G.T.5-Limited ("GT5") on May 25, 1990. In connection with a Share Exchange Agreement, on March 15, 2005 we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation, in exchange for 2,410,811 shares of our common stock (which represented approximately 81% of the total issued and outstanding shares of common stock following the close of the transaction). Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, and subsequently reorganized into a California corporation on December 11, 2000, remains the operating company under Cryoport, Inc. We became "publicly held" by the reverse merger with GT5 described above. Over time we have transitioned from being a development company to a fully operational public company, providing cold chain logistics solutions to the biotechnology and life sciences industries, globally.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Through a combination of purpose-built proprietary packaging, information technologies and specialized logistics knowhow, we provide frozen shipping logistics solutions to the life sciences industry. We view our solutions as disruptive to "older technologies" in that our solutions provide reliable, economic alternatives to existing solutions and services utilized for frozen shipping in life sciences including stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances and other items that require continuous exposure to frozen or cryogenic temperatures.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Our Cryoport Express<sup>®</sup> Solutions includes sophisticated cloud-based logistics management software we have branded as the Cryoportal™ which supports the management of the entire shipment process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. The Cryoportal™ provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal™ records and retains a fully documented "chain-of-custody" and, at the client's option, "chain-of-condition" for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our customers to meet exacting requirements necessary for scientific work and for regulatory purposes.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Our Cryoport Express<sup>®</sup> Solutions also includes our liquid nitrogen dry vapor shippers we have branded as our Cryoport Express<sup>®</sup> Shippers, which are cost-effective and reusable cryogenic transport containers (patented vacuum flasks) utilizing innovative liquid nitrogen ("LN2") "dry vapor" technology. Cryoport Express<sup>®</sup> Shippers are International Air Transport Association ("IATA") certified, and validated to maintain stable temperatures of minus 150° C and below for a 10-plus day dynamic shipment period. The Company currently features two Cryoport Express<sup>®</sup> Shipper models, the Standard Dry Shipper (holding up to 75-2.0 ml vials) and the High Volume Dry Shipper (holding up to 500-2.0 ml vials).</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Amongst our solutions, we offer a "turnkey" solution, which can be accessed through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once the order is placed, we ship a fully charged Cryoport Express® Shipper to the customer <font style="COLOR: #1a1a1a">who conveniently loads their frozen commodity into the inner chamber of the shipper.  The customer then closes the shipper and reseals the shipping box displaying the recipient's address ("Flap A") for pre-arranged carrier pick up. </font> Cryoport arranges for the pick-up of the parcel by a shipping service provider for delivery to the customer's intended recipient.  The recipient simply opens the box and shipper and removes the frozen commodity.  The recipient only needs to reseal the box, displaying the nearest Cryoport Operations Center address ("Flap B") and set it out for pre-arranged carrier pick up. The Cryoport Express<sup>®</sup> Shipper is returned to us for cleaning, quality assurance testing, recharging and reuse.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> In late 2012, we shifted our focus from being a developer of cryogenic shippers and software to being a comprehensive frozen logistics solutions provider to the life sciences industry, which was accomplished by broadening our service offerings. Now, in addition to our "Turn-key Solution", we also provide the following value-added solutions that were developed to address our various clients' needs:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td>"<strong><em>Customer Staged Solution</em></strong>," under which we supply an inventory of our Cryoport Express® Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal™ to enter orders with shipping and delivery service providers for the transportation of the package. Once the order is released, our customer services professionals monitor the shipment and the return of the shipper to us for cleaning, quality assurance testing and reuse.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td>"<strong><em>Customer Managed Solution</em></strong>," a limited customer implemented, solution, whereby we supply our Cryoport Express® Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us. Under this solution, the customer accepts a significant level of the risk for a successful shipment.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in">  </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td>"<strong><em>Powered by Cryoport</em></strong><sup>SM</sup>" is made available to providers of shipping and delivery services who seek to offer a "branded" cryogenic shipping solution as part of their service offerings. By negotiation, this solution can be private labeled as long as "<em>powered by Cryoport<sup>SM</sup></em>" appears prominently on the offering software interface and prominently on the packaging, which is provided by the client after minimum volume requirements are met.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif"> "<strong><em>Integrated Solution</em></strong>" is our most comprehensive and complex outsourcing solution. It usually involves our management of the entire cryogenic logistics process for our client, including the location of our employees at the client's site to manage the client's cryogenic logistics, in total.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td style="TEXT-ALIGN: justify">"<strong><em>Life Science Point-of-Care Repository Solution</em></strong>" whereby we supply our Cryoport Express<sup>®</sup> Shippers to ship and store cryogenically preserved life science products for up to 6 days (or longer periods with substitute Shippers) at a point-of-care site, with the Cryoport Express<sup>®</sup> Shippers serving as a temporary freezer/repository enabling the efficient distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation apparatus. Our customer services professionals monitor each shipment throughout the predetermined process including the shipment's return to Cryoport where the Cryoport Express<sup>®</sup> Shipper is cleaned, tested for quality assurance and then returned to inventory for reuse.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> </p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">·</td> <td>"<strong><em>Personalized Medicine and Cell-based Immunotherapy Solution</em></strong>" whereby our Cryoport Express<sup>®</sup> Solutions serves as an enabling technology for the safe manufacture of the rapidly expanding autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient's cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility.  The Cryoport Express<sup>®</sup> Shippers can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to patients when and where they need it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation apparatus. Our customer services professionals monitor each shipment throughout the predetermined process including the shipment's return to Cryoport where the Cryoport Express<sup>®</sup> Shipper is cleaned, tested for quality assurance and then returned to inventory for reuse.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> One of our distribution partners is Federal Express Corporation ("FedEx"). We have an agreement with FedEx to provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport's services for frozen temperature-controlled cold chain transportation as its FedEx<sup>®</sup> Deep Frozen Shipping Solution on a non-exclusive basis and at its sole expense. During fiscal year 2013, the Company worked closely with FedEx to further align its sales efforts and accelerate penetration within FedEx's life sciences customer base through improved processes, sales incentives, joint customer calls and more frequent communication at the sales and executive level. In addition, FedEx has developed a FedEx branded version of the Cryoportal<sup>TM</sup> software platform, which is "<em>powered by Cryoport</em>" for use by FedEx and its customers giving them access to the full capabilities of our logistics management platform.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> In January 2013, we entered into a master agreement ("FedEx Agreement") with FedEx renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our Cryoportal<sup>TM</sup> for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013 and, unless sooner terminated as provided in the FedEx Agreement, expires on December 31, 2015.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> Pursuant to an agreement with DHL Express (USA), Inc. ("DHL"), DHL biotechnology and life science customers have direct access to our cloud-based order entry and tracking portal to order Cryoport Express<sup>®</sup> Shippers and receive preferred DHL shipping rates. The agreement covers DHL shipping discounts that may be used to support our customers using our Cryoport Express<sup>®</sup> Solutions. In connection with the agreement, we have integrated our proprietary Cryoportal<sup>TM</sup> to DHL's tracking and billing systems to provide DHL biotechnology and life science customers with a seamless way ("<em>powered by Cryoport</em>") of shipping their critical biological material worldwide.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">   </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, the Company is providing on-site logistics personnel and its logistics management platform, the Cryoportal<sup>TM</sup>, to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoport is constantly analyzing shipping data and processes to further streamline Zoetis' logistics, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum uses of resources. The Company manages Zoetis' total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013 the agreement was amended to expand Cryoport's scope to manage all logistics of Zoetis' key frozen poultry vaccine to all Zoetis' international distribution centers as well as all domestic shipments of this vaccine. In October 2013, the agreement was further amended to further expand Cryoport's services to include the logistics management for a second poultry vaccine.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 27pt; TEXT-INDENT: -27pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 27pt"> In February 2014, we entered into a services agreement with Liventa Bioscience, Inc. ("Liventa"), a privately-held, commercial stage biotechnology company focused on cell-based, advanced biologics in the orthopedic industry. Under this agreement, Liventa will be using Cryoport Express<sup>®</sup> Solutions for the logistics of its cell-based therapies requiring cryogenic temperatures and also provide Cryoport Express<sup>®</sup> Solutions to other biologics suppliers within the orthopedic arena. The agreement combines Cryoport's proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa's distribution capability to orthopedic care providers. The implementation of Cryoport's solution will eliminate dry ice shipping and related risks of degradation and also eliminate the need for expensive onsite cryogenic freezers for storage of cell-based orthopedic therapies. This will enable Liventa to better serve small or mobile clinics, pharmacies, family practice, and orthopedic specialty care providers. Surgical centers and hospitals will also benefit from better logistics and the elimination of issues surrounding dry ice transport and storage. The agreement has an initial three-year term and may be renewed for consecutive three-year terms. Liventa also agreed to certain performance criteria and the issuance of 150,000 shares of its common stock to Cryoport in exchange for the exclusive right to offer, market and promote Cryoport Express<sup>®</sup> Solutions for cellular-based therapies requiring cryogenic temperatures for use</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> in orthopedic indications in the United States.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> <font style="FONT-SIZE: 10pt">We offer our solutions to companies in the life sciences industry and specific verticals including manufacturers of stem cells and cell lines, diagnostic laboratories, bio-pharmaceuticals, contract research organizations, in-vitro fertilization, cord blood, vaccines, tissue, animal husbandry, and other producers of commodities requiring reliable frozen solutions for logistics problems. These companies operate within heavily regulated environments and as such, changing vendors and distribution practices typically require a number of steps which may include the audit of our facilities, review of our procedures, qualifying us as a vendor, and performing test shipments. This process can take up to nine months or longer to complete prior to a potential customer adopting one or more of the Cryoport Express<sup>®</sup></font> <font style="FONT-SIZE: 10pt">Solutions.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong><em>Going Concern</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> The consolidated financial statements have been prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. Further, at March 31, 2014, we had an accumulated deficit of $85.9 million. During the year ended March 31, 2014, we used cash in operations of $4.4 million and had a net loss of $19.6 million, which included a one-time, non-cash debt conversion expense of $13.7 million.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> <font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express<sup>®</sup></font> <font style="FONT-SIZE: 10pt">Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at March 31, 2014, additional funds raised subsequent to March 31, 2014 through the current preferred stock offering (see Note 15), together with the revenues generated from our services will be sufficient to sustain our planned operations into the second quarter of fiscal year 2015; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> <font style="FONT-SIZE: 10pt">Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup>®</sup></font> <font style="FONT-SIZE: 10pt">Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management's inability to successfully achieve significant revenue increases or implement cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, the Company is seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> <strong> </strong></p> <!--EndFragment--></div> </div>
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4326022	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	909395	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-138886	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-178682	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4380659	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4785144	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-19565426	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-6382433	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1324000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14960000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1840000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1441000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1546000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-1551000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-1567000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-1717000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19565426	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6382433	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1358120	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	96000	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent		USD
CY2013Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1321664	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-6324458	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1260000	USD
CY2013Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1502	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1287000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1257000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8078	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	463169	USD
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	206305	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	5515330	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	5837174	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-5078375	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1274000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1541000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1554000	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1549000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1681000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	219500	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	192800	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	26700	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	178000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	204000	USD
CY2014	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2020-12-31
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	196505	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	138892	USD
CY2014Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	4241	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22482	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138886	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156200	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4558301	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1294500	USD
CY2014	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	326890	USD
CY2013	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1485676	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1404750	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	408892	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505485	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	24876	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		USD
CY2014	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.06	pure
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	82800	USD
CY2014	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	96000	USD
CY2013	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	96000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	409111	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	425446	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85876874	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66311448	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	2659943	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	1100539	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	488000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	580000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	757000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	835000	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	191000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	234000	USD
CY2012Q4	us-gaap	Sales Revenue Net SalesRevenueNet	307000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	368000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2304495	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5106219	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5411728	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	678119	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	693180	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-2063275	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	3729520	USD
CY2005Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	2410811	shares
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4127201	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	326890	USD
CY2014	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	20848	USD
CY2013	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	16486	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong><em>Use of Estimates</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 24.5pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company's significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, valuation of derivative liabilities and valuation of common stock, warrants and stock options issued for products or services.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <strong><em> </em></strong></p> <!--EndFragment--></div> </div>
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48850513	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37760628	shares

Files In Submission

Name	View Source	Status
0001144204-14-039508-index-headers.html	Edgar Link	pending
0001144204-14-039508-index.html	Edgar Link	pending
0001144204-14-039508.txt	Edgar Link	pending
0001144204-14-039508-xbrl.zip	Edgar Link	pending
cyrx-20130331.xml	Edgar Link	completed
cyrx-20130331.xsd	Edgar Link	pending
cyrx-20130331_cal.xml	Edgar Link	unprocessable
cyrx-20130331_def.xml	Edgar Link	unprocessable
cyrx-20130331_lab.xml	Edgar Link	unprocessable
cyrx-20130331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v382024_10k.htm	Edgar Link	pending
v382024_ex10-34.htm	Edgar Link	pending
v382024_ex10-35.htm	Edgar Link	pending
v382024_ex21.htm	Edgar Link	pending
v382024_ex23-1.htm	Edgar Link	pending
v382024_ex31-1.htm	Edgar Link	pending
v382024_ex31-2.htm	Edgar Link	pending
v382024_ex32-1.htm	Edgar Link	pending
v382024_ex32-2.htm	Edgar Link	pending
v382024_ex4-24.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2014 Q2 Form 10-K Financial Statement

#000114420414039508 Filed on June 25, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2014 Q2 Form 10-K Financial Statement

#000114420414039508 Filed on June 25, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx